Sarah Rinehart MD , Ron Blankstein MD , James L. Januzzi MD , Cian McCarthy MD , Markus Scherer MD , Wesley T. O’Neal MD, MPH , Sarah Mullen MBT , Campbell Rogers MD , Leslee J. Shaw PhD , DECIDE Investigators
{"title":"Guiding Automated Implementation Strategies for Patients With Atherosclerotic Plaque on Coronary Computed Tomographic Angiography","authors":"Sarah Rinehart MD , Ron Blankstein MD , James L. Januzzi MD , Cian McCarthy MD , Markus Scherer MD , Wesley T. O’Neal MD, MPH , Sarah Mullen MBT , Campbell Rogers MD , Leslee J. Shaw PhD , DECIDE Investigators","doi":"10.1016/j.jcmg.2025.03.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Approximately half of the patients with abnormal findings have no minimal changes in clinical management after stress testing.</div></div><div><h3>Objectives</h3><div>The primary aim of this study is to assess changes in preventive and anti-ischemic care for stable patients with atherosclerotic plaque on coronary computed tomographic angiography (CTA).</div></div><div><h3>Methods</h3><div>Projected enrollment is 20,000 patients (∼40 sites) who underwent diagnostic testing for suspected or known coronary artery disease. Changes in medical therapy (dosing and type) and coronary revascularization will be collected through an automated electronic health record data extraction through 1 year of follow-up. In select subgroups, artificial intelligence–enabled quantitative measures of coronary atherosclerotic plaque (QCPA) will be provided promptly or delayed by 90 days, such that prompt decisions guided by coronary artery disease stenosis alone can be compared with QCPA-guided treatment.</div></div><div><h3>Results</h3><div>A total of 6 care pathways will be evaluated: 1) <em>no</em> QCPA is provided (usual testing); 2) QCPA is provided but <em>delayed</em> and subsequently incorporated into a revised final report to guide patient management; 3) <em>immediate</em> QCPA is provided in nonrevascularized patients; 4) immediate QCPA is provided to patients with prior stenting in 1 vessel; 5) <em>immediate</em> QCPA is provided to asymptomatic patients referred for coronary CTA; and 6) patients referred to <em>stress testing</em> with no coronary CTA (ie, the comparator).</div></div><div><h3>Conclusions</h3><div>The DECIDE (DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management) study will enroll and characterize a broad spectrum of patients who require initiation and intensification of preventive care. The authors will use efficient and automated systems to evaluate the impact of quantitative atherosclerotic plaque measurement on preventive care that will help guide implementation strategies to improve outcomes for patients undergoing coronary CTA.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 10","pages":"Pages 1107-1115"},"PeriodicalIF":15.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Cardiovascular imaging","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936878X2500275X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Approximately half of the patients with abnormal findings have no minimal changes in clinical management after stress testing.
Objectives
The primary aim of this study is to assess changes in preventive and anti-ischemic care for stable patients with atherosclerotic plaque on coronary computed tomographic angiography (CTA).
Methods
Projected enrollment is 20,000 patients (∼40 sites) who underwent diagnostic testing for suspected or known coronary artery disease. Changes in medical therapy (dosing and type) and coronary revascularization will be collected through an automated electronic health record data extraction through 1 year of follow-up. In select subgroups, artificial intelligence–enabled quantitative measures of coronary atherosclerotic plaque (QCPA) will be provided promptly or delayed by 90 days, such that prompt decisions guided by coronary artery disease stenosis alone can be compared with QCPA-guided treatment.
Results
A total of 6 care pathways will be evaluated: 1) no QCPA is provided (usual testing); 2) QCPA is provided but delayed and subsequently incorporated into a revised final report to guide patient management; 3) immediate QCPA is provided in nonrevascularized patients; 4) immediate QCPA is provided to patients with prior stenting in 1 vessel; 5) immediate QCPA is provided to asymptomatic patients referred for coronary CTA; and 6) patients referred to stress testing with no coronary CTA (ie, the comparator).
Conclusions
The DECIDE (DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management) study will enroll and characterize a broad spectrum of patients who require initiation and intensification of preventive care. The authors will use efficient and automated systems to evaluate the impact of quantitative atherosclerotic plaque measurement on preventive care that will help guide implementation strategies to improve outcomes for patients undergoing coronary CTA.
期刊介绍:
JACC: Cardiovascular Imaging, part of the prestigious Journal of the American College of Cardiology (JACC) family, offers readers a comprehensive perspective on all aspects of cardiovascular imaging. This specialist journal covers original clinical research on both non-invasive and invasive imaging techniques, including echocardiography, CT, CMR, nuclear, optical imaging, and cine-angiography.
JACC. Cardiovascular imaging highlights advances in basic science and molecular imaging that are expected to significantly impact clinical practice in the next decade. This influence encompasses improvements in diagnostic performance, enhanced understanding of the pathogenetic basis of diseases, and advancements in therapy.
In addition to cutting-edge research,the content of JACC: Cardiovascular Imaging emphasizes practical aspects for the practicing cardiologist, including advocacy and practice management.The journal also features state-of-the-art reviews, ensuring a well-rounded and insightful resource for professionals in the field of cardiovascular imaging.